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Abstract
Background: As the long-term survival of pancreatic head malignancies remains dismal, efforts have
been made for a better patient selection and a tailored treatment. Tumour size could also be used for
patient stratification.
Methods: One hundred and fourteen patients underwent a pancreaticoduodenectomy for pancreatic
adenocarcinoma, peri-ampullary and biliary cancer stratified according to: 20 mm, 21–34 mm,
35–45 mm and >45 mm tumour size.
Results: Patients with tumour sizes of20 mm had a N1 rate of 41% and a R1/2 rate of 7%. The median
survival was 3.4 years. N1 and R1/2 rates increased to 84% and 31% for tumour sizes of 21–34 mm
(P = 0.0002 for N, P = 0.02 for R). The median survival decreased to 1.6 years (P = 0.0003). A further
increase in tumour size of 35–45 mm revealed a further increase of N1 and R1/2 rates of 93% (P < 0.0001)
and 33%, respectively. The median survival was 1.2 years (P = 0.004). Tumour sizes >45 mm were related
to a further decreased median survival of 1.1 years (P = 0.2), whereas N1 and R1/2 rates were 87% and
20%, respectively.
Discussion: Tumour size is an important feature of pancreatic head malignancies. A tumour diameter of
20 mm seems to be the cut-off above which an increased rate of incomplete resections and metastatic
lymph nodes must be encountered and the median survival is reduced.
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Introduction
Pancreatic head cancer, whether they are pancreatic ductal adeno-
carcinoma, distal cholangiocarcinoma or ampullary cancer, rep-
resents an ongoing diagnostic and therapeutic challenge. Its long-
term outcome is still worse than most other gastrointestinal
cancers, and has not much improved over the past 20 years.1–4
Modern imaging techniques are used to pre-operatively assess
the local resectability of the primary tumour, i.e. invasion of vas-
cular structures, and also to detect distant metastasis. Thereby,
precise determination of the tumour size, duodenal infiltration
and lymph node involvement often remains limited.5,6 In case of a
given operative indication, surgeons largely base their decision of
local resectability on radiological information. As segmental
resection of the infiltrated portal/mesenteric vein is now routinely
performed in many centres, resectability rates could have been
greater. Of note, while mortality significantly decreased to < 5%,
morbidity rates remain increased up to 50%.7–9 Many centres
encounter an increasing number of pancreas resections caused by
centralization of major surgery and by demographic changes as
pancreatic head cancer has a close, age-related incidence.10–12 In
spite of surgery remaining pivotal, adjuvant chemotherapy is
an accepted adjunct as its beneficial effects have been proven
by the European Study Group for Pancreatic Cancer studies.13,14
Until recently, chemotherapy was based on gemcitabine only but
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nowadays, more potent combination therapies such as folfirinox
are increasingly being used.15,16
In a modern multidisciplinary approach, a precise tumour
staging system considering all important risk factors is crucial as it
represents the common basis for all specialists involved in the
diagnosis and treatment to describe tumour-related issues. The
findings of pre-operative imaging should be integrated into
tumour classification systems in order to allow a careful patient
selection, and an individual and risk-adjusted treatment planning,
e.g. patients are excluded from a curative surgical approach if
major visceral arteries are encased by the tumour, or neoadjuvant
treatment will be indicated to downstage the primary tumour.
Post-operatively, a precise tumour classification based on his-
topathological assessment allows reliable risk estimation for
recurrence and survival, and therefore optimized adjuvant or
palliative treatment options can be considered.
The TNM system considers infiltration in adjacent tissues and
tumour size as criteria to describe primary tumours.17 Of note, the
latter criterion is only used in pancreatic adenocarcinoma to
define the T1 stage, whereas peri-ampullary and biliary tumours
are solely characterized by infiltration of the duodenum and/or
vascular structures. As a consequence, the majority of tumours are
classified as T3.18–21 This patient group is probably very heteroge-
neous and, for practical reasons, it would be helpful to have other
criteria, that are easy to assess, to further distinguish these
patients.
Tumour size could have the potential to be used as such cri-
teria as it can be considered as a surrogate parameter for tumour
volume. Based on computational models, an increased tumour
mass could impact on the occurrence of metastatic lymph nodes,
resection margins and, finally, long-term survival.22 Therefore,
the present study aimed to assess the impact of tumour size as an
independent risk factor on the pre-operative predictability of
lymph node metastasis and completeness of surgical resections
(R0 versus R1/2) of pancreatic head cancer. In addition, long-
term survival related to tumour size after a resection was also
evaluated.
Methods
Patients and data collection
From our pancreas database containing 288 pancreatectomies
between January 2000 and June 2011, 114 patients were identified
who underwent a pancreaticoduodenectomy for pancreatic, amp-
ullary and distal bile duct adenocarcinomas at the Department of
Visceral Surgery, University Hospital of Lausanne (CHUV),
Lausanne, Switzerland. Patients who were operated from 2000 to
2008 were retrospectively entered whereas since 2009 patients’
data have been collected prospectively. There were 86 pancreatic
ductal adenocarcinoma, 20 distal cholangiocarcinoma and 8 amp-
ullary carcinoma. Not included were all cases of duodenal cancer,
resections for benign diseases, patients with a total pancreatec-
tomy and pancreatic left resection, as well as cases without clear
determination of tumour size on pathological examination,
mainly in the case of a tumour not expanding as a bulky mass but
spreading tumours, e.g. malignant intraductal papillary mucinous
neoplasia of the pancreas and distal cholangiocarcinoma. Pancre-
atic resections were always performed as a classic pancreaticoduo-
denectomy (no pylorus preservation) with standard lymph node
dissection (anterior and posterior pancreaticoduodenal lymph
nodes, nodes in the lower hepatoduodenal ligament and nodes
along the right aspect of the superior mesenteric artery and
vein).23 Survival data were obtained by review of hospital records,
local tumour registry or by directly contacting the individual
patient. Informed consent was obtained from all patients. The
study was approved by the local Ethics Committee.
Definition of tumour size and groups
All tumour sizes were obtained from histopathological reports
that always include measurement of the two greatest axis of the
tumour on the fixated specimen. Formalin fixation is known to
have a shrinkage effect on tissues. This shrinkage is lower for
tumour tissue which contains less water and is estimated to be
10% less in vitro than in vivo.24 The larger diameter was considered
as the reference value of the tumour size. Four groups of tumour
size were defined. First, in a similar way to the American Joint
Committee on Cancer (AJCC) classification, group 1 was defined
as a tumour size of20 mm. Many patients had tumours of about
30 mm, reflecting an arithmetic mean and a median tumour size
of 32 and 30 mm, respectively of the entire cohort, thus all these
patients were included in group 2 (21 mm to 34 mm). Group 3
comprised tumors measuring 35 mm to 45 mm. A fourth group
of large tumors with a diameter > 45 mm was labelled as group 4.
This way of grouping created two similar groups around the
largest group of tumours of about 30 mm and the addition of a
fourth group of large tumours (Fig. 1).
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Figure 1 Distribution of tumour size in 114 resected specimens of
pancreatic head tumours
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AJCC staging and pathological parameters
Fifth, sixth and seventh editions of AJCC Cancer Staging Manuals
were used as standards throughout the 12-year study period.17,25,26
Because of the modification of the T stage definition between the
fifth and the sixth edition, pathology reports were revised and
redefined according to the seventh edition. The seventh edition of
the AJCC was also used for the prognostic group staging (stage IA,
IB, IIA, IIB, III and IV). R status of the resection was recorded and
defined as R0 if no tumour was present at the resection margin
and R1 if margins contained microscopic tumour residue.
Data analysis
The correlation of tumour size with pathological results (N and R
status) was assessed with stratification between predefined size
groups. The chi-square test and Fisher’s exact test were used on
univariate analysis to detect the ability of tumour size to predict N
positivity or R1 resection. Comparison of pathological character-
istics between T3 tumours and the other T stage was also per-
formed. The Mann–Whitney test and samples t-test were used to
compare non-parametric independent samples. The impact of
tumour size on survival was analysed and compared with AJCC
prognostic groups. The median survival and overall survival rates
were determined using Kaplan–Meier survival curves. Overall sur-
vival was defined as time span from the index operation to the
date of death due to any reason. The log-rank test was used for
comparison of different variables. Differences were considered
significant at P < 0.05. The median follow-up time was 1.4 years.
Statistics were performed using MedCalc software (MedCalc soft-
ware, Mariakerke, Belgium).
Results
Patients’ characteristics and peri-operative data of the 66 men and
48 women are shown in Table 1. The details of histopathological
assessment with special emphasize on tumour size and staging are
shown in Table 2. The majority of tumours were staged as T3 (73
of 114 specimen, 64%) and 78 patients (68%) were classified in
the IIB AJJCC prognostic groups. The tumour size group classifi-
cation showed a more equilibrated repartition of resected speci-
mens between groups with the maximal number of cases in the
group 2 (21–34 mm) containing 45 specimens (39.5%). The
median and mean tumour sizes were 30 mm (range, 10–80 mm)
and 32  14 mm, respectively. Pancreatic adenocarcinoma were
larger (median size of 30 mm) than ampullary adenocarcinoma
and distal cholangiocarcinoma with median sizes of 15 mm (P =
0.0002) and 20 mm (P = 0.002), respectively. Overall, 87 speci-
mens showed a metastatic lymph node (76.3%) and 86 resections
were R0 (75.4%).
Analysis of the large group of T3 tumours containing 73 speci-
mens, showed that mean and median tumour size, N stage, R
status and repartition of the specimen into the four size groups
did not differ between T3 tumours and other stages of tumours
(Table 3). This observation shows that T3 tumours have the same
histopathological characteristics compared with other T stage
specimens. Thus, T3 tumours are a heterogeneous group in which
risk factors for outcome could be sort out.
To analyse the value of tumour size compared with T stage as a
marker of tumour aggressiveness or severity, correlations between
these two parameters and N and R status were performed
(Table 4). N positivity was significantly lower in tumours with a
diameter20 mm compared with larger tumours with 40.7%; N1
in group 1 versus 84.4%, 92.6% and 86.7% in groups 2, 3 and 4,
respectively (P < 0.001, P < 0.001 and P = 0.008). Positive resec-
tions margins were also more frequent in larger tumours than in
tumours of group size 1. T staging also correlated well with N and
R positivity. T3 tumours of a diameter 20 mm had 53.3% of a
risk to be N1 compared with 86.2%, 89.5% and 90.0% of T3
tumours of group size 2, 3 and 4, respectively (P = 0.028, P = 0.025
and P = 0.088). The probability of positive resection margins was
also higher for large T3 tumours than small T3 tumours, but
without reaching significance (Table 4).
The overall median survival was 1.8 years and 1-, 3- and 5-year
survival were 71.3%, 30.2% and 17.5%, respectively. N stage, R
status and tumour size were a significant prognostic factor of
survival on univariate analysis, whereas AJCC prognostic groups
and T stages showed a tendency to predict survival, without statis-
tical significance (Table 5 and Fig. 2). Tumours of 20 mm had a
better survival than larger tumours (median survival of 3.4 versus
1.3 years, P < 0.001). On multivariate analysis, a R0 resection was
the only significant predictor of survival [hazard ratio (HR) 0.57,P
= 0.037] whereas a tumour size20 mm did not reach significance
(HR 0.52, P = 0.071) (Table 6). The cut-off of 20 mm was also a
significant factor of better survival for T3 tumours (median sur-
vival of 2.9 years for T3 tumours of 20 mm compared with 1.3
Table 1 Patients characteristics and peri-operative results
Gender
Male 66
Female 48
Age (years), median (range) 68 (39–85)
BMI (kg/m2), mean  SD 24  3
ASA score
1 8 (7.0%)
2 76 (66.7%)
3 27 (23.7%)
4 3 (2.6%)
Mean operative time  SD (min) 352  86
Length of hospital stay (days)
Median (range) 18 (8–85)
Mortality (30 days and inhospital) 6 (5.3%)
Morbidity (30 days and inhospital) 67 (61.5%)
Data are expressed as number of patients when not other indication.
BMI, Body Mass Index; ASA, American Society of Anesthesiologist; SD,
standard deviation.
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years for T3 tumours larger than 20 mm, P = 0.019), whereas N
stage and R status were not significant predictors of long-term
survival in the large group of T3 tumours (Table 7 and Fig. 3).
The same analysis was performed taking into account pancre-
atic ductal adenocarcinomas only (Table 8). The risk of a positive
lymph node correlated well with a tumour size of pancreatic
ductal adenocarcinoma as there were 50.0% N1 in group 1 versus
85.0%, 95.7% and 84.6% in group 2,3 and 4, respectively (P =
0.030, P = 0.005 and P = 0.169). The percentage of R1 resections
was lower for pancreatic ductal adenocarcinomas of 20 mm or less
than larger pancreatic ductal adenocarcinomas but this was not
significant. The median survival after resection of pancreatic
ductal adenocarcinomas of20 mm was 6.9 years compared with
1.3 years for tumours larger than 20 mm (P = 0.021). The N stage
was also a significant factor of survival (median survival of 3.4
years for N0 tumors compared with 1.3 years for N1, P = 0.047),
whereas R0 resections showed a median survival of 1.6 years com-
pared with 1.2 years after R1 resections (P = 0.065). Looking at
T3 pancreatic ductal adenocarcinoma seemed to show the same
Table 2 TNM classification, histopathological results and tumour size
Overall
(n = 114)
Pancreatic
adenocarcinoma
(n = 86 )
Ampullary carcinoma
(n = 20 )
Distal bile duct
adenocarcinoma
(n = 8 )
TNM
T1 4 3 1 0
T2 29 21 6 2
T3 73 58 9 6
T4 8 4 4 0
N0 27 (23.7%) 14 (16.3%) 10 3
N1 87 (76.3%) 72 (83.7%) 10 5
M1 2 2 0 0
Stage
IA 3 2 1 0
IB 9 3 5 1
IIA 14 9 3 2
IIB 78 66 7 5
III 8 4 4 0
IV 2 2 0 0
R status
R0 86 (75.4%) 27 (68.6%) 20 7
R1 28 (24.6%) 59 (31.4%) 0 1
Tumour size (mm)
Mean  SD 32  14 34  13 23  16 23  8
Median (range) 30 (10–80) 30 (18–80) 15 (10–70) 20 (15–40)
Tumour size
20 mm 27 (23.7%) 10 12 5
21–34 mm 45 (39.5%) 40 3 2
35–45 mm 27 (23.7%) 23 3 1
>45 mm 15 (13.2%) 13 2 0
SD, standard deviation.
Table 3 Comparison between T3 tumours and other T stages
T3 stage
(n = 73)
T1, T2 and T4 stages
(n = 41 )
P-value
Tumour size (mm)
Mean  SD 32  14 30  15 0.475a
Median (range) 30 (10–80) 28 (10–70) 0.343b
N stage
N0 14 (19.2%) 13 (31.7%) 0.169c
N1 59 (80.8%) 28 (68.3%)
R status
R0 53 (72.6%) 33 (80.5%) 0.376c
R1 20 (27.4%) 8 (19.5%)
Tumour size
20 mm 15 (20.5%) 12 (29.3%) 0.715c
21–34 mm 29 (39.7%) 16 (39.0%)
35–45 mm 19 (26.0%) 8 (19.5%)
>45 mm 10 (13.7%) 5 (12.2%)
aIndependent samples T-test. bMann–Whitney test. cFisher's exact test.
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Table 4 Correlation between tumour characteristics and N and R status
N0 N1 %N1 P-value R0 R1 %R1 P-value
Overall 27 87 76.3 86 28 24.6
Tumour size <0.001b 0.085b
 20 mm 16 11 40.7 25 2 7.4
21–34 mm 7 38 84.4 <0.001a 31 14 31.1 0.021a
35–45 mm 2 25 92.6 <0.001a 18 9 33.3 0.039a
>45 mm 2 13 86.7 0.008a 12 3 20.0 0.329a
TNM T stage 0.045b 0.101b
T1 3 1 25.0 4 0 0
T2 9 20 69.0 0.125a 25 4 13.8 1.000a
T3 14 59 80.8 0.032a 53 20 27.4 0.568a
T4 1 7 87.5 0.067a 4 4 50.0 0.208a
T3 stage 0.025b 0.519b
20 mm 7 8 53.3 13 2 13.3
21–34 mm 4 25 86.2 0.028a 19 10 34.5 0.171a
35–45 mm 2 17 89.5 0.025a 14 5 26.3 0.426a
>45 mm 1 9 90.0 0.088a 7 3 30.0 0.358a
aFisher's exact test. bChi-square test.
Table 5 Survival after a pancreaticoduodenectomy
N Median survival (years) 1-year survival
(%)
3-year survival
(%)
5-year survival (%) P-valuea
Overall 103 1.8 71.3 30.2 17.5
AJCC stage 0.062
IA 3 5.4 100.0 100.0 66.8
IB 9 3.4 100.0 53.4 35.7
IIA 13 2.9 77.0 43.1 43.1
IIB 68 1.7 68.9 26.5 7.8
III 8 0.8 37.5 12.5 0
IV 2 1.4 100.0 0 0
T stage 0.076
T1 4 5.4 100.0 100.0 66.8
T2 26 2.2 84.7 35.2 17.5
T3 65 1.6 69.4 25.1 13.5
T4 8 0.8 37.5 12.5 0
Tumour size 0.006
20 mm 26 3.4 96.2 52.3 40.6
21–34 mm 38 1.6 73.4 19.5 0
35–45 mm 26 1.2 49.9 18.4 6.2
>45 mm 13 1.1 53.7 43.0 43.0
Tumour size <0.001
20 mm 23 3.4 96.2 52.3 40.6
>20 mm 77 1.3 62.4 21.7 8.2
N stage 0.005
N0 26 3.4 88.3 53.5 41.2
N1 77 1.6 65.7 22.1 8.5
R status 0.008
R0 26 2.2 76.6 36.9 23.4
R1 77 1.2 57.4 13.3 0
aLog-rank test.
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tendency, but without reaching significance probably owing to the
lower number of patients in each groups (Table 8).
Discussion
Classification items of the AJCC staging system have been vali-
dated to predict outcome after resection of pancreas head malig-
nancy,27 but many other factors also impact on long-term
survival.28 Tumour size is of particular interest because it could be
determined on pre-operative imaging modalities. The present
study showed that tumour size of peri-ampullary tumours was a
good indicator of tumour aggressiveness, i.e. predicting the prob-
ability of metastatic lymph nodes and resection margins, and
correlated with long-term survival.
The role of tumour size as a possible prognostic factor for
survival has already been assessed, and the most reported size
cut-offs ranged from 20 to 30 mm.23,28–37 However, possible corre-
lations between tumour size and other risk factors impacting on
survival are largely unknown. Our finding that a larger tumour
size was associated with a higher incidence of metastatic lymph
nodes and positive resection margins at histopathological exami-
nation was at least partially confirmed by a recent study from De
Jong et al. While they found that the cut-off value of 20 mm was
not associated with a poor outcome, tumour size was strongly
associated with the risk of other adverse prognostic factors.36
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Figure 2 Kaplan–Meier estimated overall survival stratified by
tumour size
Table 6 Multivariate analysis of predictors for long-term survival
Parameter Subgroup Hazard ratio (95% CI) P-value
Tumour size (mm) 20 mm, > 20 mm 0.52 (0.25–1.05) 0.071
N stage N0, N1 0.77 (0.37–0.96) 0.485
R status R0, R1 0.57 (0.33–0.96) 0.037
Table 7 Survival after a pancreaticoduodenectomy for T3 tumours
N Median survival (years) 1-year survival (%) 3-year survival (%) 5-year survival (%) P-valuea
Tumour size 0.115
20 mm 14 2.9 92.7 44.8 44.8
21–34 mm 24 1.3 70.8 17.8 0
35–45 mm 18 1.7 61.1 27.7 9.2
>45 mm 9 0.7 44.4 22.1 22.1
Tumour size 0.019
20 mm 14 2.9 92.8 44.9 44.9
>20 mm 51 1.3 62.5 18.8 6.2
N stage 0.115
N0 13 2.9 76.9 43.3 43.3
N1 52 1.6 67.4 21.6 7.0
R status 0.109
R0 47 1.6 72.2 31.3 19.6
R1 18 1.0 61.0 8.2 0
aLog-rank test.
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In our series, the risk for metastatic lymph nodes and positive
resection margins was 40% and 7%, in the case of a tumour size
20 mm compared with > 80% and > 30% for larger tumours,
respectively. The cut-off of 20 mm was highly significant predict-
ing long-term survival with a median survival of 3.4 years for
tumours20 mm compared with 1.3 years for tumours >20 mm.
As in many other series, the subgroup of T3 tumours comprised
the majority of the resected tumours.18–21 Interestingly, the cut-off
of 20 mm was a determinant risk factor for T3 tumours; and the
long-term survival of T3 tumors20 mm was 2.9 years compared
with 1.3 years for T3 tumours > 20 mm.
In order to overcome the shortcomings of the TNM system, a
specific nomogram including various tumour-related factors and
clinical factors has been developed. As it is based on risk factors
that are only known post-operatively, adapting the pre-operative
treatment is not possible.18,20 However, based on computational
models, the probability to harbour metastasis at an initial diagno-
sis was 28% for patients with a tumour of 10 mm, compared with
73% and 94% for a tumour of 20 and 30 mm, respectively.22
Therefore, the pre-operative estimated tumour size with its risk to
be N positive and to obtain positive resection margins could be
crucial information to develop an individualized pre-operative
tumour treatment plan. This latter aspect will gain more impor-
tance as there is increasing evidence favouring neoadjuvant
treatment using a modern chemotherapeutic regimen and
radiotherapy.22,38–40
Pre-operative tumour size measurement of peri-ampullary
tumours remains difficult.41,42 There are good indications that
pancreatic adenocarcinoma are well defined with magnetic reso-
nance imaging (MRI) and this modality has been shown to get
a better tumour conspicuity than computed tomography
(CT).5MRI should be accurate for precise pre-operative tumour
measurement. MRI can be used to accurately detect an ampul-
lary carcinoma43 and endosocpic ultrasound has also been
shown to be accurate and to have a high agreement with pathol-
ogy reports.44 The detection and measurement of an extrahe-
patic cholangiocarcinoma differs if it is periductal, intraductal or
mass forming. In our series, mass-forming types were kept for
analysis. This type of tumour can be well described and meas-
ured with MRI.45
There are some limitations to this present study. First, we
included three different tumour entities that may have different
characteristics, particularly regarding long-term survival. But in
daily clinical practice, the exact tumour type often remains
unknown pre-operatively; and the indication to resect a pancre-
atic head tumour is not dependent on the final histology but
rather on local criteria of resectability. In addition, classification of
the three tumour entities is very similar. Second, patients operated
early in the series were assessed retrospectively. As the annual
number of pancreatic head resections has markedly increased
during recent years, most patients were prospectively docu-
mented. Third, we used the AJCC definition for R0, meaning that
only completely tumor-free resection margins are considered as
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Figure 3 Kaplan–Meier estimated overall survival for tumour size
20 mm versus >20 mm. (a) All tumours. (b) T3 tumours only
Definition of four size groups: Group 1: 20 mm; Group 2:
21–34 mm; Group 3: 35–45 mm; Group 4: > 45 mm
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R0. This definition has recently been challenged and, nowadays,
many centres re-define R0 as tumour cells detected up to 1 mm to
the resection margins.46 As a consequence, the role of R0 status is
currently re-evaluated, and its role as a prognostic factor may
change.
In conclusion, tumour size is an important but underestimated
risk factor to stratify patients at risk for positive lymph nodes and
resection margins. It could be easily assessed pre-operatively in
individual patients and may be helpful to tailor oncological treat-
ment for patients with pancreatic head cancer.
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